|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.03 USD | -1.08% |
|
-17.72% | -22.43% |
| Jan. 14 | NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM | |
| Jan. 12 | NovoCure Reports Rise in Q4 Preliminary Revenue | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 19.81M | -58.35M | -92.53M | -207M | -169M | |||||
Depreciation & Amortization - CF | 7.75M | 9.17M | 9.57M | 9.7M | 9.87M | |||||
Depreciation & Amortization, Total | 7.75M | 9.17M | 9.57M | 9.7M | 9.87M | |||||
Amortization of Deferred Charges, Total - (CF) | 5.91M | 4.42M | 4.35M | 4.59M | 5.14M | |||||
(Gain) Loss on Sale of Investments - (CF) | -1.25M | -238K | -4.83M | -26.4M | -28.27M | |||||
Asset Writedown & Restructuring Costs | 429K | 649K | 955K | 493K | 1.16M | |||||
Stock-Based Compensation (CF) | 75.72M | 94.9M | 107M | 116M | 160M | |||||
Tax Benefit from Stock Options | - | - | - | - | - | |||||
Other Operating Activities, Total | -699K | 3.14M | -5.47M | 66K | -2.02M | |||||
Change In Accounts Receivable | -30.35M | 5.27M | 2.55M | 29.41M | -26.36M | |||||
Change In Inventories | -2.94M | 2.48M | -4.34M | -8.92M | 2.57M | |||||
Change In Accounts Payable | 25.47M | 27.78M | 14.26M | 14.87M | 19.11M | |||||
Change in Other Net Operating Assets | -702K | -6.46M | -666K | -5.71M | 1.04M | |||||
Cash from Operations | 99.15M | 82.76M | 30.79M | -73.34M | -26.37M | |||||
Capital Expenditure | -14.97M | -24.17M | -21.36M | -27.09M | -42.86M | |||||
Investment in Marketable and Equity Securities, Total | -458M | -121M | -119M | 211M | -97.39M | |||||
Other Investing Activities, Total | - | - | - | - | - | |||||
Cash from Investing | -473M | -145M | -140M | 184M | -140M | |||||
Long-Term Debt Issued, Total | 558M | - | - | - | 96.92M | |||||
Total Debt Issued | 558M | - | - | - | 96.92M | |||||
Long-Term Debt Repaid, Total | -150M | -26K | -28K | -10K | -12.91M | |||||
Total Debt Repaid | -150M | -26K | -28K | -10K | -12.91M | |||||
Issuance of Common Stock | 31.8M | 25.73M | 15.52M | 15.8M | 6.31M | |||||
Repurchase of Common Stock | - | - | - | - | - | |||||
Issuance of Preferred Stock | - | - | - | - | - | |||||
Other Financing Activities, Total | - | - | - | - | - | |||||
Cash from Financing | 440M | 25.7M | 15.49M | 15.79M | 90.32M | |||||
Foreign Exchange Rate Adjustments | 247K | -188K | -97K | 131K | -174K | |||||
Net Change in Cash | 66.76M | -36.56M | -93.78M | 127M | -76.47M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 8.69M | 101K | 41K | 6K | 7.71M | |||||
Cash Income Tax Paid (Refund) | -3.26M | 3.11M | 5.48M | 13.66M | 23.46M | |||||
Levered Free Cash Flow | 60.45M | 98.21M | 45.95M | -10.2M | 9.29M | |||||
Unlevered Free Cash Flow | 66.97M | 97.02M | 44.74M | -11.44M | 11.99M | |||||
Change In Net Working Capital | 22.19M | -43.34M | -4.09M | -30.42M | 11.72M | |||||
Net Debt Issued / Repaid | 408M | -26K | -28K | -10K | 84.01M |
Select your edition
All financial news and data tailored to specific country editions
















